Elite Pharmaceuticals Inc (ELTP) Return on Investment ROI from the first quarter of 2026 to first quarter of 2026 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Elite Pharmaceuticals Inc   (ELTP)


Elite Pharmaceuticals Inc's ROI from its first quarter of 2026 to the first quarter of 2026 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Elite Pharmaceuticals Inc's ROI in the first quarter of 2026?
Elite Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 53.81 % in its first quarter of 2026, this is above ELTP's average return on investment of 9.02%.
Elite Pharmaceuticals Inc invested over the 12 months ending in its first quarter of 2026 $105 million

Despite the deterioration in its net income, company has improved ROI compared to the fourth quarter of 2026.

Within the Healthcare sector 22 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 129, from total ROI ranking in the fourth quarter of 2026 at 135.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
I. Quarter		 (Mar 31 2026)
IV. Quarter		 (Dec 31 2025)
III. Quarter		 (Sep 30 2025)
II. Quarter		 (Jun 30 2025)
I. Quarter
Y / Y Investment Change TTM 27.24 % 35.58 % 28.62 % 42.09 % 43.15 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 109 121 85 107 101
Return On Investment (TTM) 53.81 % 43.5 % 46.15 % 15.37 % -13.07 %
ELTP's Overall Ranking # 129 # 135 # 116 # 334 # 2850
Seq. Investment Change TTM 2.1 % 9.66 % 3.85 % 9.43 % 8.79 %
Seq. Net Income Change TTM 26.29 % 3.37 % 211.77 % - -
Net Income (TTM) in Millions 57 45 43 14 -11

ELTP Company Profile >> Back to ELTP Roi Comparisons >> See Annual ELTP Return On Investment



Return On Investment ELTP's Ranking
Within: No.
Industry # 12
Sector # 23
Overall # 129

Return On Investment Statistics
High Average Low
225.3 %
9.02 %
-303.6 %
(Jun 30 2013)   (Jun 30 2016)







Financial Statements
Elite Pharmaceuticals Inc's I. Quarter Investments $ 109 Millions ELTP's Balance sheet
Elite Pharmaceuticals Inc's I. Quarter Income $ 6 Millions Quarterly ELTP's Income Statement
ELTP's Income by Division See ELTP's Income by Division


ELTP Annual Return On Investment (Mar 31 2026)
2026		 (Mar 31 2025)
2025		 (Mar 31 2024)
2024		 (Mar 31 2023)
2023		 (Mar 31 2022)
2022
Total Investments in Millions 121 85 71 33 28
Y / Y Investment Growth 43 % 19.75 % 113.55 % 16.19 % 39.64 %
Net Income in Millions 45 -4 20 4 9
Y / Y Net Income Growth - - 464.56 % -59.97 % 74.87 %
Annual Return On Investment 37.12 % -5.1 % 28.48 % 10.77 % 31.27 %


Annual Roi Comment
In the fiscal year 2026 ROI improved to 37.12 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ELTP's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ELTP's Competitors
Subscribers only: Roi for Elite Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for ELTP's Customers

Other Ratios
ELTP's Roa ELTP's Inventory Turnover Ratio ELTP's Growth Rates ELTP's Dividend Statistics
ELTP's Profitability Ratios ELTP's Asset Turnover Ratio ELTP's Dividend Growth
ELTP's Roe ELTP's Valuation Ratios ELTP's Financial Strength Ratios ELTP's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Silexion Therapeutics Corp  127.60 %
Quince Therapeutics Inc   112.49 %
Pulmatrix Inc   108.83 %
Interpace Biosciences Inc   100.71 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Arbutus Biopharma Corp  85.89 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %

Date modified: 2026-09-12T06:10:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.